Letrozole

Small molecule

Approved / Phase 4AromataseNo featureable registry evidence
Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Every registered study for this drug was reviewed, and none was selected as featured evidence for its approved use, so its Featured trials section is empty.

Also approved (4)
US
  • Adjuvant Treatment of Early Breast Cancer Femara (letrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
  • Extended Adjuvant Treatment of Early Breast Cancer Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of Femara in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival (DFS) in patients treated with Femara for a median of 60 months [see Clinical Studies (14.2, 14.3)] .
  • First and Second-Line Treatment of Advanced Breast Cancer Femara is indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies (14.4, 14.5)].
Product first approved 1997FDA label
JP
  • Postmenopausal breast cancer (Femara Tablet 2.5mg, Novartis Pharma)
Product first approved 2006biospace.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (98)
HR+/HER2- Metastatic Breast Cancer
NCT06757634 · Celcuity Inc
2025-07-24 – 2033-07-30 · Breast Cancer
What this study did
NCT04158362 · UNICANCER
2020-06-11 – 2032-06 · Cancer Metastatic
What this study did
NCT07894328 · Jiangsu HengRui Medicine Co., Ltd.
2026-11-20 – 2031-09-30 · Breast Cancer
What this study did
NCT02947685 · Alliance Foundation Trials, LLC.
2017-06-21 – 2030-12-31 · HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
What this study did
NCT05645536 · Tolmar Inc.
2022-12-28 – 2030-03 · Breast Cancer
What this study did
NCT07061717 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-07-01 – 2029-07-01 · Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
What this study did
NCT02763566 · Eli Lilly and Company
2016-12-05 – 2028-03 · Breast Cancer
What this study did
NCT05851014 · Genor Biopharma Co., Ltd.
2022-01-14 – 2027-01-30 · Breast Cancer
What this study did
NCT04906395 · Tolmar Inc.
2021-07-01 – 2027-01-30 · Breast Cancer
What this study did
NCT00382070 · NSABP Foundation Inc
2006-08 – 2025-04 · Breast Cancer
What this study did
NCT02344472 · Prof. Wolfgang Janni
2015-09 – 2025-01-31 · Metastatic Breast Cancer
What this study did
NCT00601900 · National Cancer Institute (NCI)
2008-09-24 – 2024-01-29 · Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT03966898 · Jiangsu HengRui Medicine Co., Ltd.
2019-07-19 – 2023-12-30 · Advanced Breast Cancer
What this study did
NCT00673335 · UNICANCER
2008-05 – 2023-12 · brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
What this study did
NCT04047758 · Shengjing Hospital
2019-09-01 – 2022-09-30 · Breast Cancer
What this study did
NCT01758146 · Post Graduate Institute of Medical Education and Research, Chandigarh
2012-01 – 2020-06 · Breast Cancer
What this study did
NCT00433589 · European Organisation for Research and Treatment of Cancer - EORTC
2007-02 – 2020-03 · Breast Cancer
What this study did
NCT03096847 · Novartis Pharmaceuticals
2016-10-24 – 2020-02-06 · Advanced Metastatic Breast Cancer
What this study did
NCT02600923 · Pfizer
2016-04-15 – 2019-05-28 · Advanced Breast Cancer Female
What this study did
NCT03050398 · Novartis Pharmaceuticals
2017-06-07 – 2019-03-08 · Breast Cancer
What this study did
NCT00754845 · Canadian Cancer Trials Group
2004-11-23 – 2017-04-19 · Breast Cancer
What this study did
NCT00004205 · ETOP IBCSG Partners Foundation
1998-03 – 2016-06-30 · Breast Cancer
What this study did
NCT00893061 · Centre Oscar Lambret
2009-03-16 – 2014-11-26 · Breast Cancer
What this study did
NCT00545077 · Spanish Breast Cancer Research Group
2007-11-06 – 2014-07-24 · Breast Cancer
What this study did
NCT00403182 · Technical University of Munich
started 2006-05 · Breast Cancer
What this study did
NCT00902954 · Fudan University
2008-03 – 2011-06 · Breast Cancer
What this study did
NCT00963729 · Imperial College London
2008-09 – 2011-03 · Breast Cancer
What this study did
NCT00330317 · Novartis Pharmaceuticals
2006-02 – 2010-11-16 · Breast Cancer
What this study did
NCT00949598 · Institut du Cancer de Montpellier - Val d'Aurelle
2008-12 – 2010-10 · Breast Cancer
What this study did
NCT00171340 · Novartis Pharmaceuticals
2003-05 – 2010-02 · Bone Loss, Breast Cancer
What this study did
NCT00329940 · Novartis Pharmaceuticals
2005-11 – 2008-01 · Breast Cancer
What this study did
NCT00083993 · Wyeth is now a wholly owned subsidiary of Pfizer
2004-05 – 2006-10 · Breast Neoplasms, Neoplasm Metastasis
What this study did
NCT00097344 · Intarcia Therapeutics
2004-12 – 2006-08 · Breast Neoplasms, Neoplasms, Hormone-Dependent
What this study did
NCT00267553 · Intarcia Therapeutics
2005-11 – 2006-06 · Breast Neoplasms, Neoplasms, Hormone-Dependent
What this study did
NCT00003140 · NCIC Clinical Trials Group
1998-08-24 – 2003-10 · Breast Cancer
What this study did
Other / comorbidity
NCT04852887 · NRG Oncology
2021-06-23 – 2041-07 · Stage I Breast Cancer
What this study did
NCT06223698 · Region Örebro County
2025-05-02 – 2035-05-02 · Breast Cancer
What this study did
NCT04111978 · Swiss GO Trial Group
2020-11-05 – 2033-02-01 · Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma
What this study did
NCT06492616 · Stemline Therapeutics, Inc.
2024-09-27 – 2032-10 · Breast Cancer
What this study did
NCT05891093 · Fudan University
2023-06-01 – 2031-05-31 · Breast Cancer
What this study did
Phase 2/3 (25)
HR+/HER2- Metastatic Breast Cancer
NCT02221999 · RenJi Hospital
2013-09 – 2029-01 · Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer
What this study did
NCT05523609 · Tanta University
2022-11-01 – 2024-10 · Breast Cancer
What this study did
NCT02692755 · Georgetown University
2016-09 – 2021-03-23 · Hormone Receptor Positive HER-2 Negative Breast Cancer
What this study did
NCT00333047 · Novartis
started 2002-07 · Metastatic Breast Cancer
What this study did
NCT00535418 · Novartis Pharmaceuticals
2000-06 – 2002-07 · Breast Cancer
What this study did
Other / comorbidity
NCT07319429 · Fudan University
2026-01-25 – 2029-12-31 · Endometrial Cancer, Fertility
What this study did
NCT05316935 · Xiaojun Chen
2022-07-13 – 2028-03-30 · Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance
What this study did
NCT06379113 · Xiaojun Chen
2022-07-13 – 2028-03-30 · Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
What this study did
NCT06390904 · Xiaojun Chen
2022-07-13 – 2027-07-30 · Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
What this study did
NCT07842796 · Benha University
2024-12-15 – 2026-12-12 · Ectopic Pregnancy
What this study did
NCT03458221 · Gynaecologisch Oncologisch Centrum Zuid
2023-01-31 – 2026-10-01 · Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation, Therapy-Associated Cancer
What this study did
NCT07669402 · Tehran University of Medical Sciences
2023-12-01 – 2026-03-31 · Idiopathic Oligoasthenoteratozoospermia, Male Infertility
What this study did
NCT05454358 · Fudan University
2022-08-02 – 2025-12-01 · Endometrial Cancer
What this study did
NCT05203562 · Zagazig University
2020-06-01 – 2023-06-01 · Gestational Trophoblastic Disease
What this study did
NCT03507465 · Guangdong Provincial People's Hospital
2017-11-29 – 2020-11-29 · Breast Cancer
What this study did
NCT03373708 · Zhiyong Yu
2017-12-20 – 2019-12-20 · Breast Cancer, Chemotherapy, Endocrine Breast Diseases
What this study did
NCT05702957 · Services Institute of Medical Sciences, Pakistan
2016-09 – 2019-12 · Polycystic Ovary Syndrome, Infertility
What this study did
NCT03285802 · Greater Baltimore Medical Center
2017-09-07 – 2019-02-12 · Uterine Cancer
What this study did
NCT02946684 · Sven O. Skouby
2017-02-01 – 2018-10-30 · Infertility
What this study did
NCT01797718 · Helsinki University Central Hospital
2013-10 – 2018-02-05 · Constitutional Delay of Growth and Puberty
What this study did
NCT02939898 · Sven O. Skouby
2016-08 – 2018-01 · Infertility
What this study did
NCT03440359 · Eastern Virginia Medical School
2012-07-06 – 2017-12-30 · Polycystic Ovary Syndrome
What this study did
NCT02405156 · Ain Shams University
2015-03 – 2016-12 · Miscarriage
What this study did
NCT02401425 · Ain Shams University
2015-03 – 2015-09 · Complete Miscarriage
What this study did
NCT01218581 · Mansoura University
2005-12 – 2010-01 · the Efficacy of Aromatase Inhibitor vs. Gonadotrpins Releasing Hormone Agonists in Treating Premenopausal Women With Uterine Adenomyosis
What this study did
Phase 2 (216)
HR+/HER2- Metastatic Breast Cancer
NCT07716046 · Fudan University
2026-10-01 – 2032-12-31 · Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-positive Breast Cancer, HR+/HER2+ Breast Cancer
What this study did
NCT07679269 · Novartis Pharmaceuticals
2026-12-15 – 2032-04-20 · PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
What this study did
NCT02764541 · Dana-Farber Cancer Institute
2016-05-24 – 2031-04 · Breast Cancer
What this study did
NCT06953882 · Yale University
2025-07-09 – 2030-09 · HER2 Negative Breast Cancer
What this study did
NCT02624973 · Haukeland University Hospital
2016-04-15 – 2030-06 · Breast Cancer
What this study did
NCT07014410 · Zhejiang Cancer Hospital
2023-02-01 – 2029-12-31 · Breast Cancer
What this study did
NCT05226871 · Pfizer
2022-07-07 – 2029-12-31 · Breast Cancer, Head and Neck Cancer
What this study did
NCT04557449 · Pfizer
2020-09-23 – 2029-10-07 · Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
What this study did
NCT04606446 · Pfizer
2020-11-16 – 2029-08-27 · Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
NCT05467891 · Oana Danciu
2022-09-13 – 2029-08-15 · Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT04220476 · Weill Medical College of Cornell University
2020-03-04 – 2028-12-31 · Breast Cancer
What this study did
NCT07285382 · wanghaibo
2025-06-25 – 2028-12-31 · HR Positive HER2 Negative Advanced Breast Cancer
What this study did
NCT05286437 · National Cancer Centre, Singapore
2023-02-15 – 2028-12-31 · Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
What this study did
NCT04563507 · Weill Medical College of Cornell University
2020-11-12 – 2028-10-31 · Breast Cancer
What this study did
NCT06179303 · University of Washington
2024-07-22 – 2028-06-01 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
What this study did
NCT05872204 · Universitaire Ziekenhuizen KU Leuven
2023-11-30 – 2028-01 · Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor
What this study did
NCT04886531 · Ruth O'Regan
2022-07-21 – 2027-12-21 · Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
What this study did
NCT07054190 · Hoffmann-La Roche
2025-09-09 – 2027-09-28 · Breast Cancer
What this study did
NCT05181033 · National University Hospital, Singapore
2021-12-27 – 2027-08 · Breast Cancer
What this study did
NCT05463601 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2022-08-01 – 2026-12-31 · Metastatic Breast Cancer
What this study did
NCT04553133 · Pfizer
2020-09-16 – 2026-12-31 · Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
What this study did
NCT05766410 · National Taiwan University Hospital
2022-09-16 – 2026-09-30 · Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Therapy
What this study did
NCT05190094 · International Cancer Research Group, United Arab Emirates
2022-12-20 – 2026-06 · Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
What this study did
NCT02778685 · City of Hope Medical Center
2016-09-30 – 2026-03-30 · Metastatic Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT06630325 · OHSU Knight Cancer Institute
2025-06-24 – 2026-03-11 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
What this study did
NCT03633331 · Alliance for Clinical Trials in Oncology
2018-08-15 – 2026-02-27 · Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT00999804 · Baylor Breast Care Center
2011-10 – 2026-01 · Breast Cancer
What this study did
NCT06957379 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2024-02-29 – 2025-12 · HR+/HER2- Advanced/Metastatic Breast Cancer
What this study did
NCT05800756 · Yantai Yuhuangding Hospital
2022-08-04 – 2025-07-30 · Breast Cancer
What this study did
NCT06243185 · Fengzhi Feng
2023-11-17 – 2025-06-30 · Recurrent Ovarian Carcinoma
What this study did
NCT04603183 · MedSIR
2021-06-02 – 2025-06-30 · Breast Cancer Metastatic
What this study did
NCT04942899 · Assiut University
2023-08-30 – 2025-05-31 · Metastasis Breast
What this study did
NCT04300790 · MedSIR
2020-10-23 – 2025-03-16 · Breast Cancer
What this study did
NCT06654570 · Helsinki University Central Hospital
2020-04-08 – 2024-10-10 · Breast Cancer
What this study did
NCT03822468 · Novartis Pharmaceuticals
2019-06-11 – 2024-08-30 · Breast Cancer
What this study did
NCT05469750 · Fujian Medical University Union Hospital
2022-08-10 – 2024-08 · Advanced Breast Cancer
What this study did
NCT05163106 · University Hospital, Akershus
2022-12-01 – 2024-07-30 · Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, Locally Advanced Breast Cancer, Luminal A Breast Cancer, Luminal B Breast Cancer
What this study did
NCT02188745 · Dartmouth-Hitchcock Medical Center
2016-03-11 – 2024-07-05 · Metastatic Breast Cancer
What this study did
NCT02648477 · City of Hope Medical Center
2016-03-28 – 2023-12-30 · Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
What this study did
NCT05004142 · Ahon Pharmaceutical Co., Ltd.
2020-06-30 – 2023-06-30 · Breast Neoplasms
What this study did
NCT03644186 · ETOP IBCSG Partners Foundation
2019-04-16 – 2023-04-14 · Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
What this study did
NCT04407988 · Hunan Cancer Hospital
2019-11-06 – 2023-03-31 · Metastatic Breast Cancer
What this study did
NCT03007979 · Washington University School of Medicine
2017-06-15 – 2023-03-31 · Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
What this study did
NCT02894398 · iOMEDICO AG
2016-09-06 – 2023-02-15 · Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
What this study did
NCT04129216 · Johns Hopkins University
2019-02-20 – 2022-11-10 · Breast Cancer
What this study did
NCT03691493 · Emory University
2019-02-08 – 2022-10-13 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT02806050 · University Medical Center Groningen
2016-09-16 – 2022-09-28 · Breast Cancer
What this study did
Phase 1/2 (35)
HR+/HER2- Metastatic Breast Cancer
NCT07570966 · Novartis Pharmaceuticals
2026-06-30 – 2031-08-01 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer (mCRPC)
What this study did
NCT07288359 · Novartis Pharmaceuticals
2025-12-29 – 2031-05-09 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
What this study did
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT06998407 · Avenzo Therapeutics, Inc.
2025-08-20 – 2030-08 · HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
What this study did
NCT05768139 · Eli Lilly and Company
2023-04-17 – 2030-07 · Breast Cancer, Solid Tumors, Adult
What this study did
NCT05867251 · Avenzo Therapeutics, Inc.
2023-08-30 – 2030-01-31 · Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
What this study did
NCT07389733 · Shandong Suncadia Medicine Co., Ltd.
2026-03-27 – 2028-12 · Advanced Unresectable or Metastatic Breast Cancer of Adults
What this study did
NCT06555068 · Jiangsu HengRui Medicine Co., Ltd.
2024-08-12 – 2028-08 · Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors
What this study did
NCT05262400 · Pfizer
2022-03-14 – 2027-02-26 · Breast Cancer, Solid Tumors
What this study did
NCT01872260 · Novartis Pharmaceuticals
2013-10-22 – 2027-02-26 · Breast Cancer
What this study did
NCT06974929 · Jiangsu HengRui Medicine Co., Ltd.
2025-05-22 – 2026-12 · Breast Cancer
What this study did
NCT04539496 · Sihuan Pharmaceutical Holdings Group Ltd.
2018-05-22 – 2025-12-31 · Metastasis Solid Tumors, Advanced Breast Cancer
What this study did
NCT03772353 · Fudan University
2019-05-12 – 2025-12-10 · Breast Cancer
What this study did
NCT04282031 · Beta Pharma (Suzhou) Co., Ltd.
2020-06-15 – 2025-06-30 · Advanced Solid Tumor, HR+/HER2- Breast Cancer
What this study did
NCT03774472 · M.D. Anderson Cancer Center
2018-08-20 – 2024-04-17 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT03913234 · Yonsei University
2019-06-10 – 2023-10-30 · HER2-positive Breast Cancer, Postmenopausal, Metastatic Breast Cancer
What this study did
NCT00634634 · Rutgers, The State University of New Jersey
2008-08-11 – 2023-04-28 · Metastatic Breast Cancer
What this study did
NCT03054363 · University of Colorado, Denver
2017-11-27 – 2023-02-07 · Breast Cancer
What this study did
NCT02520063 · University of Alabama at Birmingham
2015-02-01 – 2022-12-01 · Breast Cancer
What this study did
NCT03481998 · Jiangsu HengRui Medicine Co., Ltd.
2018-03-22 – 2022-07-30 · Advanced Breast Cancer
What this study did
NCT04488107 · Ahon Pharmaceutical Co., Ltd.
2019-02-14 – 2022-06-30 · Breast Neoplasms
What this study did
NCT03709082 · University of Kansas Medical Center
2018-10-15 – 2021-02-03 · HER2-positive Breast Cancer, Breast Cancer Metastatic
What this study did
NCT01791985 · Imperial College London
2012-07 – 2018-12 · Breast Cancer
What this study did
NCT01105312 · Alliance for Clinical Trials in Oncology
2010-09 – 2013-09-03 · Breast Cancer
What this study did
NCT01082068 · Sanofi
2010-06 – 2013-04 · Breast Cancer
What this study did
Other / comorbidity
NCT04486352 · Alliance Foundation Trials, LLC.
2021-10-20 – 2027-10 · Endometrial Cancer
What this study did
NCT07767435 · Sohag University
2026-08-01 – 2027-06-01 · Abortion Induced Complicated, Abortion
What this study did
NCT02562118 · National University Hospital, Singapore
2015-10-02 – 2027-06 · Breast Cancer
What this study did
NCT06706414 · Martin Blomberg Jensen
2025-03-01 – 2026-08-15 · Infertility, Male
What this study did
NCT05705505 · Traws Pharma, Inc.
2023-03-29 – 2026-02 · Endometrioid Endometrial Cancer
What this study did
NCT05918718 · Tehran University of Medical Sciences
2023-01-20 – 2024-12-20 · Ectopic Pregnancy
What this study did
NCT01686828 · University of Washington
2013-06 – 2017-12 · Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
What this study did
NCT00290745 · University of California, San Francisco
2002-02-19 – 2011-06-30 · Breast Cancer
What this study did
NCT00823004 · Yazd Research & Clinical Center for Infertility
2008-06 – 2009-10 · Ovarian Stimulation
What this study did
NCT00351416 · Massachusetts General Hospital
2004-01-21 – 2009-06-29 · Healthy Volunteers
What this study did
Phase 1 (74)
HR+/HER2- Metastatic Breast Cancer
NCT06139107 · Mridula George, MD
2024-08-22 – 2032-09-30 · Breast Cancer
What this study did
NCT07604571 · Novartis Pharmaceuticals
2026-05-28 – 2032-06-08 · Advanced HR+/HER2- Breast Cancer
What this study did
NCT07897721 · Pfizer
2026-11-09 – 2032-03-21 · Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Metastatic Colorectal Adenocarcinoma
What this study did
NCT06120283 · BeOne Medicines
2023-12-01 – 2029-12 · Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
What this study did
NCT04316169 · Medical College of Wisconsin
2021-10-21 – 2028-01 · Solid Tumor, Advanced Breast Cancer
What this study did
NCT07029399 · NiKang Therapeutics, Inc.
2025-03-25 – 2027-12-31 · HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
What this study did
NCT07923214 · Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
2024-07-02 – 2027-12 · Advanced Solid Tumors, Breast Cancer, Ovarian Cancer, Gastric Cancer, Other Solid Tumors
What this study did
NCT02057133 · Eli Lilly and Company
2014-03-10 – 2026-12 · Breast Neoplasms
What this study did
NCT05238831 · OHSU Knight Cancer Institute
2023-01-30 – 2026-05-31 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT06570031 · Ono Pharmaceutical Co., Ltd.
2021-11-09 – 2026-04-30 · Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
What this study did
NCT06253195 · BeOne Medicines
2024-04-01 – 2026-04-23 · Advanced Solid Tumor, Metastatic Solid Tumor, Hormone-receptor-positive Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer
What this study did
NCT03900884 · Peter MacCallum Cancer Centre, Australia
2019-09-25 – 2026-03-19 · Breast Neoplasm Female
What this study did
NCT04630210 · Universitaire Ziekenhuizen KU Leuven
2021-02 – 2025-01-31 · Breast Cancer
What this study did
NCT02499146 · Pfizer
2015-09-11 – 2024-12-24 · Advanced Breast Cancer
What this study did
NCT03962647 · Vanderbilt-Ingram Cancer Center
2019-07-08 – 2024-07-14 · Estrogen Receptor-positive Breast Cancer
What this study did
NCT05337657 · Genor Biopharma Co., Ltd.
2021-06-02 – 2024-02-01 · Advanced Breast Cancer
What this study did
NCT06047184 · BeBetter Med Inc
2019-07-15 – 2024-01-30 · Advanced Breast Cancer
What this study did
NCT03554044 · University of California, San Francisco
2020-02-05 – 2023-12-31 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
What this study did
NCT04872608 · Memorial Sloan Kettering Cancer Center
2021-09-09 – 2023-04-25 · Metastatic Breast Cancer, Unresectable Breast Cancer
What this study did
NCT03308201 · Tianjin Hemay Pharmaceutical Co., Ltd
2017-10-16 – 2023-03-01 · Breast Cancer
What this study did
NCT04856371 · Haihe Biopharma Co., Ltd.
2021-04 – 2022-12 · Advanced Breast Cancer
What this study did
NCT01791478 · Vanderbilt-Ingram Cancer Center
2013-04 – 2022-10-06 · Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT03128619 · Jonsson Comprehensive Cancer Center
2017-08-02 – 2022-03-31 · Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Postmenopausal, Progesterone Receptor Positive, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT01870505 · Memorial Sloan Kettering Cancer Center
2013-05 – 2022-02-28 · Metastatic or Locally-advanced Unresectable Breast Cancer
What this study did
NCT01655225 · Eli Lilly and Company
2012-07-31 – 2022-02-02 · Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Malignant Mesothelioma, Non-small Cell Lung Cancer
What this study did
NCT02152943 · M.D. Anderson Cancer Center
2014-07-17 – 2020-12-14 · Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal, Premenopausal, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Refractory Hormone Receptor Positive Breast Carcinoma, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT02538484 · The University of Texas Health Science Center at San Antonio
2016-04 – 2020-03-26 · Breast Cancer
What this study did
NCT02619162 · Centro Nacional de Investigaciones Oncologicas CARLOS III
2015-07 – 2018-06 · Breast Cancer
What this study did
NCT02154776 · Novartis Pharmaceuticals
2014-06-27 – 2016-10-26 · Advanced or Metastatic Breast Cancer
What this study did
NCT01248494 · Vanderbilt-Ingram Cancer Center
2010-11 – 2016-05 · Metastatic Breast Cancer
What this study did
NCT01077453 · National Cancer Institute (NCI)
2010-03 – 2014-06 · Healthy, no Evidence of Disease, Lobular Breast Carcinoma in Situ
What this study did
NCT01199367 · Kyowa Kirin Co., Ltd.
2010-12 – 2012-12 · Breast Cancer
What this study did
NCT00516542 · OHSU Knight Cancer Institute
2007-06 – 2010-12 · Breast Cancer
What this study did
NCT01367626 · Roxane Laboratories
2008-03 – 2008-04 · Breast Cancer
What this study did
NCT01367652 · Roxane Laboratories
2008-03 – 2008-04 · Breast Cancer
What this study did
Other / comorbidity
NCT07401381 · Rovi Pharmaceuticals Laboratories
2026-06-08 – 2028-10 · Hormone Receptor Positive Early Breast Cancer
What this study did
NCT05464810 · Emory University
2022-09-02 – 2028-04-15 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma
What this study did
NCT03122197 · University of Cincinnati
2017-05-16 – 2027-12 · Brain Tumor
What this study did
NCT04895761 · Providence Health & Services
2021-09-10 – 2026-09-01 · Breast Cancer
What this study did
NCT06315205 · Rovi Pharmaceuticals Laboratories
2023-07-26 – 2026-03-11 · Healthy
What this study did
NCT06813118 · HITEC-Institute of Medical Sciences
2024-06-07 – 2025-03-25 · Polycystic Ovarian Syndrome
What this study did
NCT05157672 · Washington State University
2021-12-14 – 2024-08-31 · Interaction Drug Food
What this study did
NCT03401320 · Rovi Pharmaceuticals Laboratories
2017-11-06 – 2024-05-17 · Healthy
What this study did
Phase 4 (60)
HR+/HER2- Metastatic Breast Cancer
NCT05161195 · Novartis Pharmaceuticals
2022-07-07 – 2030-08-14 · Metastatic Breast Cancer
What this study did
NCT04289805 · Erasme University Hospital
2019-02-25 – 2025-01-15 · Breast Neoplasm Malignant Female
What this study did
NCT02661932 · Erasme University Hospital
2012-11 – 2024-12 · Breast Neoplasms, Fertility
What this study did
NCT01035099 · Weill Medical College of Cornell University
2009-11 – 2022-09-30 · Breast Cancer, Infertility
What this study did
NCT03220178 · Palleos Healthcare GmbH
2017-07-24 – 2021-12-07 · Breast Neoplasm
What this study did
NCT02679755 · Pfizer
2016-03-09 – 2019-07-25 · Breast Cancer
What this study did
NCT01612871 · Institut Claudius Regaud
2012-06-27 – 2016-01-28 · Breast Cancer
What this study did
NCT01553903 · Institut Claudius Regaud
2011-12 – 2013-05 · Breast Cancer
What this study did
NCT00375752 · Novartis Pharmaceuticals
2006-06-01 – 2010-12-16 · Breast Neoplasms
What this study did
NCT00237133 · Novartis Pharmaceuticals
2003-03 – 2009-01-21 · Locally Advanced Breast Cancer
What this study did
NCT00171847 · Novartis Pharmaceuticals
2003-03 – 2008-10 · Metastatic Breast Cancer
What this study did
NCT00237224 · Novartis Pharmaceuticals
2003-02 – 2007-02 · Breast Cancer
What this study did
NCT00241046 · Novartis Pharmaceuticals
2002-04 – 2005-03 · Metastatic Breast Cancer
What this study did
NCT00014638 · Novartis
2001-01 – 2002-03 · Breast Cancer
What this study did
Other / comorbidity
NCT07508657 · Kirstine Kirkegaard
2026-08-28 – 2030-01 · Infertility
What this study did
NCT04321551 · University of California, San Diego
2023-07-01 – 2028-12-31 · Transgender, Healthy
What this study did
NCT06143631 · University of California, San Francisco
2024-07-24 – 2028-12-11 · Leiomyoma, Uterine, Leiomyoma, Fibroid, Fibroid Uterus
What this study did
NCT06354439 · Hospital de Clinicas de Porto Alegre
2024-03-27 – 2026-12-31 · Ectopic Pregnancy
What this study did
NCT06985186 · University of Palermo
2025-06 – 2026-12 · Adenomyosis of Uterus, Infertility Assisted Reproductive Technology
What this study did
NCT04137640 · Shengjing Hospital
2021-07-19 – 2026-05-31 · Breast Cancer
What this study did
NCT05183828 · University of Washington
2022-01-23 – 2026-05-13 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma of No Special Type
What this study did
NCT05809024 · Yongsheng Wang
2023-03-01 – 2026-03-25 · Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer
What this study did
NCT05206448 · Rachel Mejia
2020-10-26 – 2025-12 · Polycystic Ovary Syndrome, PCOS, Infertility
What this study did
NCT07160855 · Nishtar Medical University
2025-05-13 – 2025-11-12 · Miscarriage in First Trimester, Missed Miscarriage
What this study did
NCT05341817 · KK Women's and Children's Hospital
2022-11-22 – 2025-11 · Abortion in First Trimester
What this study did
NCT07589075 · Beni-Suef University
2023-10-20 – 2025-10-30 · Induction of Ovulation, PCO - Polycystic Ovaries
What this study did
NCT03238703 · Fred Hutchinson Cancer Center
2018-09-01 – 2025-03-14 · HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage 0 Breast Cancer, Stage IA Breast Cancer
What this study did
NCT06181305 · Rahem Fertility Center
2024-02-24 – 2024-12-25 · IVF
What this study did
NCT05168865 · Dubai Fertility Center
2023-08-01 – 2024-04-01 · Frozen Embryo Transfer, Polycystic Ovarian Disease, Letrozole, Hormone Replacement Therapy, Live Birth, Miscarriage
What this study did
NCT05362799 · Menoufia University
2022-06-01 – 2023-12-31 · Infertility, Female
What this study did
NCT05205837 · Copenhagen University Hospital, Rigshospitalet
2021-11-24 – 2023-08-15 · Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism
What this study did
NCT04002635 · CRG UZ Brussel
2020-12-01 – 2022-04-01 · Infertility, Female, Polycystic Ovary Syndrome, IVF, Ovulation Disorder
What this study did
NCT04069117 · Mansoura University Hospital
2019-08-01 – 2022-02-20 · Polycystic Ovarian Syndrome
What this study did
NCT05198141 · Zagazig University
2020-12-15 – 2022-01-01 · Ectopic Pregnancy
What this study did
NCT04331197 · Cairo University
2020-05-01 – 2021-06-01 · Subfertility
What this study did
NCT04590482 · Shereen Rady Abou El-fetouh
2020-11-15 – 2021-05-08 · Missed Abortion
What this study did
NCT04364581 · Mansoura University
2020-05-01 – 2021-05-01 · Myoma;Uterus
What this study did
NCT03901170 · National Taiwan University Hospital
2019-04-25 – 2021-04-08 · Investigative Techniques, Reproductive Techniques, Reproductive Techniques, Assisted
What this study did
NCT04159649 · Mansoura University
2019-12-01 – 2020-12-30 · EMBRYO IMPLANTATION
What this study did
NCT02703649 · Mount Sinai Hospital, Canada
2016-03 – 2020-07-31 · Anovulation
What this study did
NCT04215835 · Cairo University
2020-01-05 – 2020-04-10 · Missed Abortion
What this study did
NCT04217265 · Cairo University
2020-01-05 – 2020-04-10 · Missed Abortion
What this study did
NCT04834791 · Tanta University
2019-03-01 – 2019-10-31 · Clomiphene Citrate Resistance, Ovulation Induction, Letrozole, Gonadotropins
What this study did
NCT02802865 · Rachel Mejia
2016-08 – 2019-02 · Polycystic Ovary Syndrome, Infertility
What this study did
NCT02137538 · Stanford University
2009-11-18 – 2018-06-05 · Short Stature
What this study did
NCT02470741 · University of California, San Francisco
2015-07 – 2017-12 · Leiomyoma, Uterine Fibroids
What this study did
NCT01908556 · Institut fuer Frauengesundheit
2009-02 – 2015-12 · is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.
What this study did
NCT02097680 · University Hospital, Ghent
2013-12 – 2015-06 · Obesity
What this study did
NCT02288143 · University of Sao Paulo
2015-01 – 2015-03 · Infertility
What this study did
NCT00478504 · University of Nottingham
2007-05 – 2014-09 · Infertility, Polycystic Ovarian Syndrome
What this study did
Early phase / not applicable (76)
HR+/HER2- Metastatic Breast Cancer
NCT06235931 · Second Affiliated Hospital of Soochow University
2024-02-01 – 2026-12-01 · Breast Neoplasms
What this study did
NCT01720602 · University of Washington
2012-11 – 2020-01 · Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT00504699 · New York Medical College
2002-01 – 2018-03-01 · Breast Cancer
What this study did
NCT01669343 · Samuel Lunenfeld Research Institute, Mount Sinai Hospital
2012-10 – 2016-12 · Breast Neoplasms
What this study did
NCT01153672 · University of Washington
2010-11 – 2016-08-11 · Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT00114270 · University of Virginia
2004-05 – 2007-06 · Breast Cancer, Osteoporosis
What this study did
Other / comorbidity
NCT06733727 · The University of Hong Kong
2024-12-06 – 2028-06-05 · Silent Miscarriage
What this study did
FET in Adenomyosisnot yet recruiting
NCT06913075 · Indira IVF Hospital Pvt Ltd
2027-01-16 – 2027-12-23 · Adenomyosis
What this study did
NCT07065539 · First Affiliated Hospital, Sun Yat-Sen University
2025-07-20 – 2027-12 · Adenomyosis of Uterus, Frozen Embryo Transfer (FET)
What this study did
NCT06006091 · International Peace Maternity and Child Health Hospital
2023-08-01 – 2027-08-01 · Letrozole, Infertility, Female
What this study did
NCT05487092 · The University of Hong Kong
2022-12-01 – 2027-06-30 · Endometriotic Cyst of Ovary
What this study did
NCT07753655 · Cairo University
2026-08-15 – 2027-03-01 · Letrozole
What this study did
NCT07425990 · University of Novi Sad
2026-03-13 – 2027-03 · Infertility Female, Frozen Embryo Transfer (FET)
What this study did
NCT07448272 · Mst.Sumyara Khatun
2025-04-01 – 2026-10-01 · PCOS (Polycystic Ovary Syndrome)
What this study did
NCT07379502 · CMH Kharian Medical College
2026-03-05 – 2026-08-31 · Polyendocrine Metabolic Ovarian Syndrome (PMOS)
What this study did
NCT07873294 · Al-Azhar University
2025-08-01 – 2026-08-10 · Polycystic Ovary Syndrome
What this study did
NCT07159880 · GABRIEL MONTEIRO PINHEIRO
2025-09-01 – 2026-07-30 · PCOS (Polycystic Ovary Syndrome), Infertility, Anovulation
What this study did
NCT07255911 · Mst.Sumyara Khatun
2025-02-07 – 2026-06-30 · PCOS
What this study did
NCT04169451 · Peking University Third Hospital
2022-09-29 – 2026-06 · Intrauterine Insemination, Unexplained Infertility
What this study did
NCT07777640 · Bangladesh Medical University
2025-06-01 – 2026-05-28 · Polycystic Ovary Syndrome (PCOS)
What this study did
NCT06372119 · Mỹ Đức Hospital
2024-04-22 – 2026-04 · Embryo Transfer, Irregular Menstruation, Letrozole, Hormone Replacement Therapy
What this study did
NCT07636317 · Sohag University
2025-06-14 – 2026-03-01 · Letrozole, Misoprostol, Induction, Missed Abortion
What this study did
NCT07759518 · Mst.Sumyara Khatun
2025-02-01 – 2026-02-01 · PCOS
What this study did
NCT06793904 · Cairo University
2025-02-01 – 2026-01 · Polycystic Ovarian Syndrome (PCOS)
What this study did
NCT07109947 · Aswan University
2025-07-10 – 2025-12-10 · Miscarriage
What this study did
NCT05940233 · Queen Savang Vadhana Memorial Hospital, Thailand
2023-06-30 – 2025-05-30 · Medical; Abortion, Fetus
What this study did
NCT05166668 · Menoufia University
2021-11-01 – 2025-02-10 · Ovarian Stimulation
What this study did
NCT05227391 · Reproductive & Genetic Hospital of CITIC-Xiangya
2022-03-16 – 2024-12-31 · PCOS
What this study did
NCT07922512 · Mst.Sumyara Khatun
2023-07-01 – 2024-12-31 · Oligospermia
What this study did
NCT06507332 · Egymedicalpedia
2024-03-01 – 2024-09-10 · Polycystic Ovary Syndrome
What this study did
NCT02095184 · University of Maryland, Baltimore
2015-05-25 – 2024-08-02 · Breast Cancer
What this study did
NCT07168837 · Al-Azhar University
2023-01-10 – 2024-05-10 · PCOS (Polycystic Ovary Syndrome)
What this study did
NCT06413771 · Uludag University
2023-01-01 – 2024-02-01 · Infertility Unexplained
What this study did
NCT06426979 · Zagazig University
2023-01-01 – 2024-01-01 · Pregnancy Tubal
What this study did
NCT05839574 · Jagiellonian University
2021-01-01 – 2023-10-30 · Cesarean Scar Pregnancy
What this study did
NCT05839561 · Jagiellonian University
2020-12-01 – 2023-06-30 · Tubal Pregnancy Unruptured
What this study did
NCT05198050 · Cairo University
2022-04-03 – 2022-09-30 · Anembryonic Pregnancy
What this study did
NCT04308343 · Assiut University
2020-03-30 – 2022-09-01 · Ectopic Pregnancy
What this study did
NCT05437471 · Universiti Kebangsaan Malaysia Medical Centre
2020-01-01 – 2022-05-30 · Miscarriage, Recurrent
What this study did
NCT05075863 · Nishtar Medical University
2021-01-01 – 2021-06-30 · Polycystic Ovary Syndrome
What this study did
NCT04193930 · Assiut University
2021-01-01 – 2021-01-01 · ART
What this study did
NCT02701348 · NHS Tayside
2016-05 – 2020-12-24 · Breast Cancer
What this study did
NCT04310293 · Al Baraka Fertility Hospital
2020-03-10 – 2020-08-01 · Poor Ovarian Response
What this study did
NCT02775877 · Navy General Hospital, Beijing
2016-05 – 2020-01 · Female Infertility Due to Nonimplantation of Ovum
What this study did
NCT03455426 · Peking University Third Hospital
2018-03-15 – 2019-12-31 · Infertility, Intrauterine Insemination
What this study did
NCT03540979 · Meir Medical Center
2018-06 – 2019-12 · Reproductive Behavior
What this study did
NCT04619914 · Laylay Mohammed Khalleefah Alhibshi
2019-03-01 – 2019-08-10 · Endometrial Thickness, Pregnancy Rate
What this study did
Used as active comparator (41)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (20)
HR+/HER2- Metastatic Breast Cancer
NCT07085767 · Olema Pharmaceuticals, Inc.
2025-11-03 – 2032-01 · Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
What this study did
NCT04964934 · AstraZeneca
2021-06-30 – 2028-09-01 · ER-Positive HER2-Negative Breast Cancer
What this study did
NCT04546009 · Hoffmann-La Roche
2020-10-09 – 2028-07-28 · Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
What this study did
NCT06016738 · Olema Pharmaceuticals, Inc.
2023-11-16 – 2028-02-29 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
What this study did
NCT07024173 · Shandong Suncadia Medicine Co., Ltd.
2025-07-23 – 2027-12 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT05909397 · Pfizer
2023-08-09 – 2026-12-30 · Breast Cancer
What this study did
NCT04478266 · Sanofi
2020-10-14 – 2023-05-26 · Breast Cancer
What this study did
NCT00044291 · Intarcia Therapeutics
2002-06 – 2006-01 · Breast Neoplasms, Neoplasms, Hormone-dependent
What this study did
Other / comorbidity
NCT05952557 · AstraZeneca
2023-10-05 – 2037-05-06 · Breast Cancer, Early Breast Cancer
What this study did
NCT05774951 · AstraZeneca
2023-03-31 – 2036-05-29 · Breast Cancer, Early Breast Cancer
What this study did
NCT05512364 · European Organisation for Research and Treatment of Cancer - EORTC
2023-12-15 – 2035-11-01 · ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
What this study did
NCT07190443 · Japanese Foundation for Cancer Research
2025-02-07 – 2035-02-06 · Breast Cancer, Locoregional Recurrence, Abemaciclib, Endocrine Therapy
What this study did
NCT07349069 · Shandong Suncadia Medicine Co., Ltd.
2026-03-04 – 2034-01 · Breast Cancer
What this study did
NCT07019363 · Fudan University
2025-06-15 – 2033-04-15 · Breast Cancer, Adjuvant Therapy
What this study did
NCT05514054 · Eli Lilly and Company
2022-10-04 – 2032-03 · Breast Neoplasms
What this study did
NCT06671912 · Alliance for Clinical Trials in Oncology
2025-02-19 – 2031-11-30 · Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
What this study did
NCT06072781 · Verastem, Inc.
2024-03-18 – 2031-02-09 · Low Grade Serous Ovarian Cancer
What this study did
NCT04134598 · Azienda Ospedaliero-Universitaria Careggi
2021-02-08 – 2030-03-31 · Breast Cancer
What this study did
NCT03625531 · Hongxia Ma
2018-08-13 – 2025-01-22 · Polycystic Ovary Syndrome
What this study did
NCT07143682 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2023-01-08 – 2024-06-30 · Polycystic Ovarian Syndrome (PCOS), Infertility
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT02101788 · National Cancer Institute (NCI)
2014-04-11 – 2025-10-27 · Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
What this study did
Phase 2 (14)
HR+/HER2- Metastatic Breast Cancer
NCT07729046 · University of California, San Diego
2027-07 – 2035-06 · Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
What this study did
NCT04985266 · Royal Marsden NHS Foundation Trust
2022-03-30 – 2030-09-01 · ER+ Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT04059484 · Sanofi
2019-10-22 – 2025-01-02 · Breast Cancer Metastatic
What this study did
NCT04256941 · M.D. Anderson Cancer Center
2019-05-31 – 2023-09-22 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT03024580 · Instituto Nacional de Cancer, Brazil
2017-03-06 – 2020-09 · Breast Neoplasm
What this study did
NCT02491983 · MedSIR
2015-08 – 2020-01 · Metastatic Breast Cancer
What this study did
NCT00728949 · Eli Lilly and Company
2008-08 – 2015-02 · Metastatic Breast Cancer
What this study did
NCT00770354 · Antisoma Research
2008-09 – 2011-08 · Breast Carcinoma
What this study did
Other / comorbidity
NCT06075953 · QuantumLeap Healthcare Collaborative
2024-02-17 – 2033-11 · Ductal Carcinoma in Situ
What this study did
NCT05472792 · UNC Lineberger Comprehensive Cancer Center
2022-05-17 – 2032-04-15 · Breast Cancer, Quality of Life
What this study did
NCT02482740 · Buddhist Tzu Chi General Hospital
2015-05 – 2017-06 · Uterine Cervical Neoplasms
What this study did
Early phase / not applicable (6)
HR+/HER2- Metastatic Breast Cancer
NCT02583828 · Capital Medical University
2015-06 – 2021-12 · Breast Neoplasms, Neoplasm Metastasis
What this study did
Other / comorbidity
NCT07766590 · Bangladesh Medical University
2025-06-01 – 2026-05-28 · Insulin Resistant PCOS
What this study did
NCT05106712 · Umm Al-Qura University
2021-11-01 – 2023-11-01 · Female Infertility, Polycystic Ovary Syndrome, Pathologic Processes, Vitamin D Deficiency, IVF, Vitamin D Supplement
What this study did
NCT05874518 · Liuzhou Maternity and Child Healthcare Hospital
2021-12-01 – 2022-04-30 · Warm Needling, Electroacupuncture, Ovulation Dysfunction
What this study did
NCT02630485 · University of British Columbia
2015-12 – 2018-08 · Polycystic Ovary Syndrome, Infertility
What this study did
NCT02377479 · University Hospitals Cleveland Medical Center
2015-03 – 2017-03 · Infertility
What this study did
Appears in other studies (38)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (18)
HR+/HER2- Metastatic Breast Cancer
NCT06507618 · University of Virginia
2024-07-19 – 2034-03-01 · Breast Cancer Female
What this study did
NCT07174336 · Eli Lilly and Company
2025-12-22 – 2033-05 · Breast Neoplasms, Neoplasm Metastasis
What this study did
NCT04584853 · Institute of Cancer Research, United Kingdom
2020-12-23 – 2030-10 · Breast Cancer Female
What this study did
NCT05257395 · Xuanzhu Biopharmaceutical Co., Ltd.
2022-03-14 – 2030-09-05 · Advanced Breast Cancer
What this study did
NCT01674140 · SWOG Cancer Research Network
2013-09-12 – 2030-01 · Breast Cancer
What this study did
NCT02246621 · Eli Lilly and Company
2014-11-06 – 2026-12 · Breast Cancer
What this study did
NCT05207709 · SOLTI Breast Cancer Research Group
2022-03-28 – 2026-03-26 · Metastatic Breast Cancer
What this study did
NCT02278120 · Novartis Pharmaceuticals
2014-11-20 – 2023-04-20 · Advanced Metastatic Breast Cancer
What this study did
NCT01958021 · Novartis Pharmaceuticals
2013-12-17 – 2023-03-16 · Advanced, Metastatic Breast Cancer
What this study did
NCT00073528 · Novartis Pharmaceuticals
2003-12-09 – 2018-03-22 · Breast Neoplasms
What this study did
Other / comorbidity
NCT00310180 · National Cancer Institute (NCI)
2006-04-07 – 2030-09-30 · Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIB Breast Cancer AJCC v7
What this study did
NCT02918084 · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
2013-06 – 2028-06 · Breast Cancer
What this study did
NCT06405243 · Beni-Suef University
2024-06-05 – 2025-11-01 · Polycystic Ovary Syndrome
What this study did
NCT05712941 · EQRx International, Inc.
2023-04-18 – 2025-03 · Endometrial Carcinoma
What this study did
NCT02980965 · Fudan University
2013-05 – 2017-02 · Breast Cancer Female
What this study did
Phase 2/3 (1)
HR+/HER2- Metastatic Breast Cancer
NCT00684216 · The Netherlands Cancer Institute
2008-04 – 2013-05 · Breast Cancer
What this study did
Phase 2 (15)
HR+/HER2- Metastatic Breast Cancer
NCT06465368 · Pfizer
2024-07-11 – 2025-07-10 · Breast Cancer
What this study did
NCT03671330 · Novartis Pharmaceuticals
2018-08-29 – 2025-05-09 · Breast Cancer
What this study did
NCT05085002 · EQRx, Inc.
2021-12-21 – 2023-11-29 · Advanced Breast Cancer
What this study did
NCT03306472 · Cambridge University Hospitals NHS Foundation Trust
2017-07-20 – 2023-10-31 · Breast Cancer
What this study did
NCT02115048 · Translational Research in Oncology
2014-07 – 2018-11 · Breast Neoplasms
What this study did
NCT00880009 · Pfizer
2009-07-30 – 2010-05-31 · Breast Cancer
What this study did
Other / comorbidity
NCT07492394 · Hebei Medical University Fourth Hospital
2025-09-12 – 2031-12-31 · Breast Cancer
What this study did
NCT07179939 · Fudan University
2025-09-10 – 2031-12-30 · HER2-positive Breast Cancer
What this study did
NCT02712723 · Qamar Khan
2016-02 – 2026-12 · Breast Cancer
What this study did
NCT04272801 · Shayna Showalter, MD
2020-04-07 – 2026-06-01 · Breast Cancer Female
What this study did
NCT02273973 · Genentech, Inc.
2014-11-12 – 2017-03-13 · Breast Cancer
What this study did
NCT01919229 · Novartis Pharmaceuticals
2013-10 – 2014-09 · Early Breast Cancer
What this study did
NCT00422903 · GlaxoSmithKline
2007-04 – 2011-04 · Neoplasms, Breast
What this study did
Phase 1 (1)
HR+/HER2- Metastatic Breast Cancer
NCT05307705 · Eli Lilly and Company
2022-05-11 – 2026-12 · Breast Cancer
What this study did
Phase 4 (2)
HR+/HER2- Metastatic Breast Cancer
Other / comorbidity
NCT01127295 · Institut Claudius Regaud
2010-06-17 – 2017-12-01 · Hormono-depending Adjuvant Breast Cancer
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT06041204 · Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy
2021-05-06 – 2026-06-28 · PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Subclinical Hypothyroidism, Female Infertility
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for HR+/HER2- Metastatic Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Letrozole: this drugApprovedSmall moleculeAromatasenot yet graded
NCT00003140: Estimated 4-year disease-free survival: letrozole 93% vs placebo 87% (75 vs 132 recurrences/new cancers out of 5187 enrolled); P<=0.001 phase 3 result · pivotal pending
NCT00004205: Disease-free survival (primary endpoint), letrozole vs tamoxifen: 5-year DFS 84.0% vs 81.4%; HR 0.81 (95% CI 0.70-0.93), P=0.003, at median follow-up 25.8 months (351 vs 428 events; N=8010). phase 3 result · pivotal pending
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
AnastrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00291759: Recurrence-free survival, 2yr tamoxifen then 3yr anastrozole vs 5yr tamoxifen: HR 0.80 (95% CI 0.63-1.01), P=.06 (not statistically significant) missed phase 3 result · pivotal pending
NCT00300508: At a median follow-up of 62.3 months, women who received anastrozole (n=387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer or distant metastasis) versus women who received no further treatment (n=469): hazard ratio 0.62 (95% CI 0.40-0.96), P=.031. phase 3 result · pivotal pending
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)Partial signal
NCT00002662: ORR (the registered first objective) 32% vs 25% (P=.10); OS 15.4 vs 12.7 months (P=.03) and TTP 5.7 vs 3.6 months (P<.0001) favored docetaxel. missed
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Weak signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromatasePartial signal
NCT00002777: Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). missed
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Weak signal
NCT00128310: Median progression-free survival: 6.0 months (gemcitabine + vinorelbine) vs 4.0 months (vinorelbine alone); hazard ratio 0.66 (p=0.0028). Overall survival not significantly different (15.9 vs 16.4 months, p=0.8046)
NCT00006459: Eli Lilly's pivotal phase III global registration trial of gemcitabine + paclitaxel vs paclitaxel alone in anthracycline-pretreated advanced breast cancer, matching this listing's title/sponsor. Primary endpoint (overall survival): 18.6 vs 15.8 months, HR 0.78 (95% CI 0.64-0.96), p=0.0187, favoring the gemcitabine combination.
GoserelinApprovedPeptideGnRH receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
AfuresertibPhase 3Small moleculeAKT (inhibitor)Partial signal
NCT04851613: Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15).
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
AtirmociclibPhase 3Small moleculeCDK4Partial signal
NCT06465368: Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 (Day 14): PF-07220060 + Letrozole 88.2% (95% CI 76.6-94.5) vs Letrozole Alone 17.9% (95% CI 10.0-29.8)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
BGB-43395Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
BireociclibPhase 3Small moleculeCDK2/4/6Reliable signal
NCT05077449: BRIGHT-2 (NCT05077449), primary endpoint median PFS: bireociclib (XZP-3287) + fulvestrant 14.7 months vs placebo + fulvestrant 7.3 months; HR 0.54 (95% CI 0.40-0.74); p<0.001
ChidamidePhase 3Small moleculeHDACReliable signal
NCT02482753: Investigator-assessed median PFS: 7.4 months (95% CI 5.5-9.2) chidamide+exemestane vs 3.8 months (95% CI 3.7-5.5) placebo+exemestane; hazard ratio 0.755, p=0.0336
CulmerciclibPhase 3Small moleculeCDK2/CDK4/CDK6, CDK2/4/6/CDK4Partial signal
NCT05375461: Median investigator-assessed PFS: 16.6 months (culmerciclib + fulvestrant) vs 7.5 months (placebo + fulvestrant); HR 0.36 (95% CI 0.26-0.51), P<0.001, meeting the primary endpoint.
DalpiciclibPhase 3Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLnot yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2Partial signal
NCT03052634: Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months
GiredestrantPhase 3Small moleculeEstrogen receptorPartial signal
NCT04546009: persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. missed
HRS-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
HRS-8080Phase 3Small moleculeEstrogen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
JS105Phase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication
NTQ1062Phase 3Small moleculeAKT (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
PalazestrantPhase 3Small moleculeEstrogen receptorWeak signalNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
PembrolizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PrifetrastatPhase 3Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SaruparibPhase 3Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
SHR-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
Sirolimus For Injection (Albumin-Bound)Phase 3Small moleculemTOR (mechanistic target of rapamycin complex 1), via FKBP-12not yet gradedNo reviewed efficacy summary in this indication
TaragarestrantPhase 3Small moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 3Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
Tibremciclib (Kangmeina)Phase 3Small moleculeCDK4 and CDK6Partial signal
NCT05433480: Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesnot yet gradedNo reviewed efficacy summary in this indication
Zoledronic AcidPhase 3Small moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
ZovegalisibPhase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 43 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(104 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Letrozole to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (11)
December 2026 (11)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT06974929 · CT.gov ↗
What to watch
Phase 2Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial CancerRecruiting
Est. primary completion 2026-12 · NCT05997017 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT05780567 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04486911 · CT.gov ↗
What to watch
Phase 2Endometrial CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04393285 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-22 · NCT04886531 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT03006172 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04553133 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05286437 · CT.gov ↗
What to watch
Phase 4Ectopic PregnancyRecruiting
Est. primary completion 2026-12-31 · NCT06354439 · CT.gov ↗
What to watch
Early phase / not applicableEndometriotic Cyst of OvaryRecruiting
Est. primary completion 2026-12-31 · NCT05487092 · CT.gov ↗
What to watch
2027 (36)
January 2027 (3)
Phase 1/2Breast CancerActive not recruiting
Est. primary completion 2027-01 · NCT02562118 · CT.gov ↗
What to watch
Phase 1/2Abortion Induced Complicated, AbortionNot yet recruiting
Est. primary completion 2027-01-01 · NCT07767435 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-01-30 · NCT04906395 · CT.gov ↗
What to watch
February 2027 (4)
Early phase / not applicableInfertility Female, Frozen Embryo Transfer (FET)Recruiting
Est. primary completion 2027-02 · NCT07425990 · CT.gov ↗
What to watch
Phase 3Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma …Active not recruiting
Est. primary completion 2027-02-01 · NCT04095364 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02-26 · NCT05262400 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02-26 · NCT01872260 · CT.gov ↗
What to watch
March 2027 (4)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-03 · NCT07305246 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03-01 · NCT06179303 · CT.gov ↗
What to watch
Early phase / not applicableLetrozoleNot yet recruiting
Est. primary completion 2027-03-01 · NCT07753655 · CT.gov ↗
What to watch
Phase 2Endometrial Neoplasm Malignant Stage IActive not recruiting
Est. primary completion 2027-03-10 · NCT05247268 · CT.gov ↗
What to watch
April 2027 (5)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT07923214 · CT.gov ↗
What to watch
Phase 2Low-Grade Serous Ovarian CancerRecruiting
Est. primary completion 2027-04 · NCT06394804 · CT.gov ↗
What to watch
Phase 1Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2027-04-15 · NCT05464810 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-04-15 · NCT04614194 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05900206 · CT.gov ↗
What to watch
May 2027 (1)
Early phase / not applicableAdenomyosis of Uterus, Frozen Embryo Transfer (FET)Not yet recruiting
Est. primary completion 2027-05 · NCT07065539 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Ectopic PregnancyNot yet recruiting
Est. primary completion 2027-06 · NCT07624903 · CT.gov ↗
What to watch
July 2027 (4)
Phase 2Hormone Receptor-Positive, HER2-Negative, Node Positive Breast CancerNot yet recruiting
Est. primary completion 2027-07 · NCT07394946 · CT.gov ↗
What to watch
Phase 2Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal CarcinomaRecruiting
Est. primary completion 2027-07-01 · NCT04469764 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-31 · NCT07029399 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-07-31 · NCT07054190 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-08 · NCT05181033 · CT.gov ↗
What to watch
September 2027 (3)
Phase 1Brain TumorRecruiting
Est. primary completion 2027-09-01 · NCT03122197 · CT.gov ↗
What to watch
Phase 2Endometrial Cancer, Recurrent Endometrial Cancer, TP53Recruiting
Est. primary completion 2027-09-01 · NCT06366347 · CT.gov ↗
What to watch
Early phase / not applicableAdenomyosisNot yet recruiting
Est. primary completion 2027-09-15 · NCT06913075 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Breast Cancer, Early-stage Breast CancerEnrolling by invitation
Est. primary completion 2027-10-01 · NCT06650748 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-10-31 · NCT04563507 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Malignant NeoplasmRecruiting
Est. primary completion 2027-11-04 · NCT06979596 · CT.gov ↗
What to watch
December 2027 (7)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12 · NCT06555068 · CT.gov ↗
What to watch
Phase 2Breast NeoplasmsNot yet recruiting
Est. primary completion 2027-12 · NCT07935317 · CT.gov ↗
What to watch
Early phase / not applicableSilent MiscarriageNot yet recruiting
Est. primary completion 2027-12-05 · NCT06733727 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT07014410 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT07285382 · CT.gov ↗
What to watch
Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2/3Endometrial Cancer, FertilityRecruiting
Est. primary completion 2027-12-31 · NCT07319429 · CT.gov ↗
What to watch
2028 (23)
January 2028 (3)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01 · NCT05872204 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Breast Cancer, Breast NeoplasmsNot yet recruiting
Est. primary completion 2028-01-30 · NCT07691333 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-31 · NCT05867251 · CT.gov ↗
What to watch
February 2028 (2)
Phase 3Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC) …Active not recruiting
Est. primary completion 2028-02-01 · NCT04111978 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2028-02-28 · NCT04931342 · CT.gov ↗
What to watch
March 2028 (5)
Phase 2Hormone-receptor-positive Breast Cancer, Early Breast CancerNot yet recruiting
Est. primary completion 2028-03-01 · NCT07676331 · CT.gov ↗
What to watch
Phase 2Breast Cancer, HR Positive, HER2 Positive Breast CancerNot yet recruiting
Est. primary completion 2028-03-30 · NCT07795424 · CT.gov ↗
What to watch
Phase 2/3Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone ResistanceRecruiting
Est. primary completion 2028-03-30 · NCT05316935 · CT.gov ↗
What to watch
Phase 2/3Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance, ObesityRecruiting
Est. primary completion 2028-03-30 · NCT06379113 · CT.gov ↗
What to watch
Phase 3InfertilityRecruiting
Est. primary completion 2028-03-31 · NCT03011684 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Breast Cancer, ER Positive Breast CancerActive not recruiting
Est. primary completion 2028-04-02 · NCT04568616 · CT.gov ↗
What to watch
May 2028 (2)
Phase 1Hormone Receptor Positive Early Breast CancerRecruiting
Est. primary completion 2028-05 · NCT07401381 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2028-05-31 · NCT05891093 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Uterine LeiomyosarcomaRecruiting
Est. primary completion 2028-07-30 · NCT05649956 · CT.gov ↗
What to watch
August 2028 (5)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08 · NCT06998407 · CT.gov ↗
What to watch
Phase 2Endometrial CancerRecruiting
Est. primary completion 2028-08-01 · NCT03675893 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-08-01 · NCT07900516 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08-15 · NCT05467891 · CT.gov ↗
What to watch
Phase 2Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Carcinoma …Active not recruiting
Est. primary completion 2028-08-31 · NCT03008408 · CT.gov ↗
What to watch
September 2028 (2)
Phase 4Leiomyoma, Uterine, Leiomyoma, Fibroid, Fibroid UterusRecruiting
Est. primary completion 2028-09-11 · NCT06143631 · CT.gov ↗
What to watch
Phase 2Invasive Breast Cancer (Stage I-III)Not yet recruiting
Est. primary completion 2028-09-30 · NCT07801898 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12 · NCT07389733 · CT.gov ↗
What to watch
Phase 2Breast Cancer, HER2-positiveRecruiting
Est. primary completion 2028-12-29 · NCT05035836 · CT.gov ↗
What to watch
2029 (15)
January 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2029-01-02 · NCT06760637 · CT.gov ↗
What to watch
February 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-02 · NCT07340658 · CT.gov ↗
What to watch
March 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-03-31 · NCT06757634 · CT.gov ↗
What to watch
April 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-04 · NCT07492641 · CT.gov ↗
What to watch
June 2029 (1)
Phase 4InfertilityRecruiting
Est. primary completion 2029-06 · NCT07508657 · CT.gov ↗
What to watch
July 2029 (2)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-07-01 · NCT07061717 · CT.gov ↗
What to watch
Phase 3Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2029-07-31 · NCT07391774 · CT.gov ↗
What to watch
August 2029 (2)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2029-08 · NCT06492616 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-08-27 · NCT04606446 · CT.gov ↗
What to watch
September 2029 (2)
Phase 3Early Breast CancerActive not recruiting
Est. primary completion 2029-09-07 · NCT05827081 · CT.gov ↗
What to watch
Phase 3Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of OvaryRecruiting
Est. primary completion 2029-09-22 · NCT05601700 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-10-07 · NCT04557449 · CT.gov ↗
What to watch
December 2029 (3)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12 · NCT06120283 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2029-12-31 · NCT05226871 · CT.gov ↗
What to watch
2030 (9)
March 2030 (2)
Phase 3HR+/HER2- Metastatic Breast CancerEnrolling by invitation
Est. primary completion 2030-03 · NCT05645536 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-03-22 · NCT07897721 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-06-28 · NCT05161195 · CT.gov ↗
What to watch
July 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
August 2030 (2)
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-08-15 · NCT07867262 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-08-31 · NCT07716046 · CT.gov ↗
What to watch
September 2030 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09 · NCT06953882 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
2031 (5)
April 2031 (1)
Phase 3Stage I Breast CancerRecruiting
Est. primary completion 2031-04-08 · NCT04852887 · CT.gov ↗
What to watch
May 2031 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-05-09 · NCT07288359 · CT.gov ↗
What to watch
July 2031 (1)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2031-07-30 · NCT07894328 · CT.gov ↗
What to watch
December 2031 (2)
Phase 2Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast CancerNot yet recruiting
Est. primary completion 2031-12 · NCT07101159 · CT.gov ↗
What to watch
Phase 2Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases, CDK4/6 Inhibitor, HR+/HER2- Breast CancerRecruiting
Est. primary completion 2031-12-31 · NCT07581834 · CT.gov ↗
What to watch
2032 (4)
March 2032 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2032-03-23 · NCT07679269 · CT.gov ↗
What to watch
May 2032 (1)
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2032-05-02 · NCT06223698 · CT.gov ↗
What to watch
June 2032 (1)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2032-06-08 · NCT07604571 · CT.gov ↗
What to watch
October 2032 (1)
Phase 2Brest Cancer ER+ and HER2 NegativeNot yet recruiting
Est. primary completion 2032-10 · NCT07866430 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Phase 2Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast CancerRecruiting
Est. primary completion 2034-07-01 · NCT06348134 · CT.gov ↗
What to watch

See the full readout calendar ↗